1419221-46-7

Basic information

• Product Name: N-(6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
• Synonyms: N-(6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
• CAS NO: 1419221-46-7
• Molecular Weight: 398.334
• Mol File: 1419221-46-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide(1419221-46-7)
• EPA Substance Registry System: N-(6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide(1419221-46-7)

Safety Data

• Hazardous Substances Data: 1419221-46-7(Hazardous Substances Data)

Upstream product

• 7496-50-6 2-amino-6-methyl-4,5,6,7-tetrahydrobenzothiazol-7-one 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 

Relevant articles and documents

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.